MX357717B - Un ensayo de respuesta inmunitaria mediada por células con sensibilidad potenciada. - Google Patents
Un ensayo de respuesta inmunitaria mediada por células con sensibilidad potenciada.Info
- Publication number
- MX357717B MX357717B MX2013015259A MX2013015259A MX357717B MX 357717 B MX357717 B MX 357717B MX 2013015259 A MX2013015259 A MX 2013015259A MX 2013015259 A MX2013015259 A MX 2013015259A MX 357717 B MX357717 B MX 357717B
- Authority
- MX
- Mexico
- Prior art keywords
- enhanced sensitivity
- immune response
- assay
- cell mediated
- mediated immune
- Prior art date
Links
- 238000003556 assay Methods 0.000 title abstract 4
- 230000035945 sensitivity Effects 0.000 title abstract 2
- 230000021633 leukocyte mediated immunity Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invención se refiere a un método para medir la actividad de la respuesta inmunitaria mediada por células en un sujeto, dicho método caracterizado porque comprende co-incubar una muestra de sangra que comprende linfocitos del sujeto con por lo menos dos conjuntos de péptidos, un primer conjunto que comprende por un péptido de 7 a 14 residuos de aminoácidos en longitud que se reconocen por los linfocitos CD8+ y un segundo conjunto que comprende por lo menos un péptido de 16 residuos de aminoácidos o mayor que se reconocen por los linfocitos CD4+, cuyos péptidos abarcan todo o parte de un antígeno proteico, y que miden la presencia o elevación en el nivel de una molécula efectora inmuntaria de las células inmunitarias en donde la presencia o nivel de la molécula efectora inmunitaria es indicativo del nivel de la sensibilidad medidas por células del sujeto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161502811P | 2011-06-29 | 2011-06-29 | |
| PCT/AU2012/000756 WO2013000021A1 (en) | 2011-06-29 | 2012-06-27 | A cell mediated immune response assay with enhanced sensitivity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013015259A MX2013015259A (es) | 2014-04-16 |
| MX357717B true MX357717B (es) | 2018-07-20 |
Family
ID=47423289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013015259A MX357717B (es) | 2011-06-29 | 2012-06-27 | Un ensayo de respuesta inmunitaria mediada por células con sensibilidad potenciada. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9983207B2 (es) |
| EP (2) | EP3351936A1 (es) |
| JP (1) | JP6150177B2 (es) |
| KR (1) | KR102022513B1 (es) |
| CN (3) | CN108593936B (es) |
| AU (4) | AU2012276280B2 (es) |
| BR (1) | BR112013033520B1 (es) |
| CA (1) | CA2840484C (es) |
| CY (1) | CY1120633T1 (es) |
| DK (1) | DK2726883T4 (es) |
| ES (1) | ES2673697T5 (es) |
| HU (1) | HUE037801T2 (es) |
| LT (1) | LT2726883T (es) |
| MX (1) | MX357717B (es) |
| PT (1) | PT2726883T (es) |
| RU (2) | RU2018107763A (es) |
| SI (1) | SI2726883T2 (es) |
| TR (1) | TR201808740T4 (es) |
| WO (1) | WO2013000021A1 (es) |
| ZA (1) | ZA201309155B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2367561B1 (en) | 2008-11-30 | 2015-05-20 | Immusant, Inc. | Compositions and methods for treatment of celiac disease |
| JP2012167952A (ja) * | 2011-02-10 | 2012-09-06 | Central Automotive Products Ltd | アルコール検知器 |
| SI2726883T2 (sl) | 2011-06-29 | 2022-09-30 | Cellestis Limited | Test celično posredovanega imunskega odziva s povečano občutljivostjo |
| JP6123282B2 (ja) * | 2012-12-20 | 2017-05-10 | 富士電機株式会社 | プログラマブルコントローラおよび電源切断対処方法 |
| HUE038527T2 (hu) * | 2012-12-28 | 2018-10-29 | Cellestis Ltd | Sejtek által közvetített immunválasz |
| JP2014229116A (ja) * | 2013-05-23 | 2014-12-08 | 富士電機株式会社 | プログラマブルコントローラおよび電源切断対処方法 |
| CA2923822A1 (en) | 2013-09-10 | 2015-03-19 | Immusant, Inc. | Dosage of a gluten peptide composition |
| AU2015323979A1 (en) | 2014-09-29 | 2017-05-18 | Immusant, Inc. | Use of HLA genetic status to assess or select treatment of celiac disease |
| EP3210015A1 (en) * | 2014-10-23 | 2017-08-30 | Qiagen Sciences, LLC | Peptide composition and uses thereof |
| EP3302457A2 (en) | 2015-06-08 | 2018-04-11 | Lophius Biosciences GmbH | Composition for determination of cell-mediated immune responsiveness |
| GB201605210D0 (en) * | 2016-03-29 | 2016-05-11 | Oxford Immunotec Ltd | Assay |
| AU2019253924A1 (en) * | 2018-04-19 | 2020-11-26 | StickyCell Pty Ltd | Leukocyte recruitment in infectious disease |
| EP3775894B1 (en) * | 2018-05-11 | 2024-04-24 | OBI Pharma, Inc. | Method for predicting human immune response |
| JP6796737B1 (ja) * | 2020-06-02 | 2020-12-09 | 振武 曽 | 多項目自動血球計数装置 |
| EP4179328A2 (en) * | 2020-07-10 | 2023-05-17 | Covid Diagnostics Ltd. | Compositions, methods, and systems for detecting immune response |
| CN114062665B (zh) * | 2020-08-05 | 2023-04-28 | 菲鹏生物股份有限公司 | 示踪粒子标记目标分子及其制备方法和应用 |
| CN113238060B (zh) * | 2021-05-08 | 2022-10-11 | 迈克生物股份有限公司 | 用于预测或诊断心肌炎的试剂盒 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US20020131976A1 (en) † | 1998-12-23 | 2002-09-19 | Ajit Lalvani | Tuberculosis vaccine |
| DE60130435T2 (de) * | 2000-02-24 | 2009-07-23 | Invitrogen Corp., Carlsbad | Gleichzeitige stimulation und konzentration von zellen |
| AUPQ689900A0 (en) | 2000-04-14 | 2000-05-11 | Commonwealth Scientific And Industrial Research Organisation | Bubble acoustics |
| DK1432439T3 (da) * | 2001-10-02 | 2006-04-03 | Mologen Ag | Middel til forbedring af immunsvaret |
| WO2004004758A1 (en) * | 2002-07-05 | 2004-01-15 | Lipoxen Technologies Limited | Method to enhance an immune response of nucleic acid vaccination |
| ITRM20040091A1 (it) † | 2004-02-19 | 2004-05-19 | Istituto Naz Per Le Malattie | Test immunologico rapido per la diagnosi ed il monitoraggio dell'infezione tubercolare. |
| EP1751181B1 (en) | 2004-06-02 | 2012-08-15 | AdAlta Pty Ltd | BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS |
| AU2008229636B2 (en) * | 2007-03-16 | 2014-08-14 | QIAGEN Australia Holding Pty. Ltd. | A cell-mediated immune response assay and kits therefor |
| BRPI0817052A2 (pt) * | 2007-08-30 | 2015-03-24 | Genentech Inc | Métodos para o tratamento de uma doença auto-imune e distúrbio, método de inibição de atividade biológica, método para aumentar uma atividade biológica, método para a detecção de uma doença auto-imune, população de células t cd4+, método para isolar uma população de células t cd4+, kit, uso de um modulador crtam, modulador crtam e anticorpo. |
| EP2106803A1 (en) | 2008-04-04 | 2009-10-07 | Fondazione Centro San Raffaele del Monte Tabor | Method to design and uses of overlapping peptides for monitoring T-cell responses in HIV patients |
| NZ588406A (en) * | 2008-04-23 | 2012-05-25 | Healthlinx Ltd | An assay comprising determining levels of biomarkers including ca125 and at least one selected from agr-2, midkine and crp for detecting a gynecological condition |
| CA2731854C (en) * | 2008-07-25 | 2020-06-30 | Cellestis Limited | Measurement of cell-mediated immune response reactivity to detect or monitor a disease or condition |
| US9459253B2 (en) * | 2009-12-23 | 2016-10-04 | Cellestis Limited | Assay for measuring cell-mediated immunoresponsiveness |
| SI2726883T2 (sl) | 2011-06-29 | 2022-09-30 | Cellestis Limited | Test celično posredovanega imunskega odziva s povečano občutljivostjo |
-
2012
- 2012-06-27 SI SI201231303T patent/SI2726883T2/sl unknown
- 2012-06-27 WO PCT/AU2012/000756 patent/WO2013000021A1/en active Application Filing
- 2012-06-27 CN CN201810440565.XA patent/CN108593936B/zh active Active
- 2012-06-27 LT LTEP12804281.9T patent/LT2726883T/lt unknown
- 2012-06-27 BR BR112013033520-3A patent/BR112013033520B1/pt active IP Right Grant
- 2012-06-27 CN CN201280031730.7A patent/CN103703375B/zh active Active
- 2012-06-27 KR KR1020147002072A patent/KR102022513B1/ko active IP Right Grant
- 2012-06-27 MX MX2013015259A patent/MX357717B/es active IP Right Grant
- 2012-06-27 RU RU2018107763A patent/RU2018107763A/ru unknown
- 2012-06-27 TR TR2018/08740T patent/TR201808740T4/tr unknown
- 2012-06-27 HU HUE12804281A patent/HUE037801T2/hu unknown
- 2012-06-27 EP EP18158828.6A patent/EP3351936A1/en active Pending
- 2012-06-27 EP EP12804281.9A patent/EP2726883B2/en active Active
- 2012-06-27 DK DK12804281.9T patent/DK2726883T4/da active
- 2012-06-27 AU AU2012276280A patent/AU2012276280B2/en active Active
- 2012-06-27 CN CN202210619543.6A patent/CN115144594A/zh active Pending
- 2012-06-27 US US14/129,517 patent/US9983207B2/en active Active
- 2012-06-27 CA CA2840484A patent/CA2840484C/en active Active
- 2012-06-27 RU RU2013154967A patent/RU2647468C2/ru active
- 2012-06-27 JP JP2014517329A patent/JP6150177B2/ja active Active
- 2012-06-27 ES ES12804281T patent/ES2673697T5/es active Active
- 2012-06-27 PT PT128042819T patent/PT2726883T/pt unknown
-
2013
- 2013-12-05 ZA ZA2013/09155A patent/ZA201309155B/en unknown
-
2017
- 2017-08-09 AU AU2017213471A patent/AU2017213471A1/en not_active Abandoned
-
2018
- 2018-04-25 US US15/962,988 patent/US20190101536A1/en not_active Abandoned
- 2018-05-16 CY CY181100505T patent/CY1120633T1/el unknown
-
2019
- 2019-08-30 AU AU2019222928A patent/AU2019222928B2/en active Active
-
2022
- 2022-04-28 AU AU2022202799A patent/AU2022202799A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013015259A (es) | Un ensayo de respuesta inmunitaria mediada por celulas con sensibilidad potenciada. | |
| Braun et al. | Presence of SARS-CoV-2-reactive T cells in COVID-19 patients and healthy donors | |
| EP3546939A3 (en) | An assay for measuring cell-mediated immunoresponsiveness | |
| Yin et al. | HLA-DM constrains epitope selection in the human CD4 T cell response to vaccinia virus by favoring the presentation of peptides with longer HLA-DM–mediated half-lives | |
| Yang et al. | CD4+ T cells recognize unique and conserved 2009 H1N1 influenza hemagglutinin epitopes after natural infection and vaccination | |
| Chang et al. | Analysis of total immunoglobulin E and specific immunoglobulin E of 3,721 patients with allergic disease | |
| BR112015005308A2 (pt) | dispositivo de aquisição de imagem por ultrassonografia tridimensional e sistema de formação de imagem por ultrassonografia | |
| RU2013139476A (ru) | Способ обнаружения проницаемости кишечного, а также гематоэнцефалического барьера и материалы для соответствующих тестов | |
| Gambichler et al. | Occurrence of circulating anti-bullous pemphigoid antibodies in patients with lichen sclerosus. | |
| WO2013164763A3 (en) | A biological complex specific for alzheimer's disease detection in vitro and use thereof | |
| FR2896588B1 (fr) | Methode de diagnostic in vitro de reponse immunitaire autoimmune par detection d'anticorps diriges contre l'antigene pentraxine 3. | |
| MA46814B2 (fr) | Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet | |
| JP2016509609A5 (es) | ||
| RU2015130287A (ru) | Адаптация вируса гриппа н5 к человеку | |
| US20180318386A1 (en) | Peptides and methods of treating endometriosis using the same | |
| WO2011109112A3 (en) | Method of detecting tau protein and tau fragments in serum | |
| Hirokawa et al. | Expression of genes encoding inflammasome sensor subunits in the duodenal and colonic mucosae of dogs with chronic enteropathy | |
| Muris et al. | Palladium allergy prevalence is underestimated because of an inadequate test allergen. | |
| Jagtap et al. | sMAdCAM: iL-6 ratio influences disease progression and anti-viral responses in SARS-CoV-2 infection | |
| Moreews et al. | Superantigenic TCR Vbeta 21.3 signature in Multisystem Inflammatory Syndrome in Children | |
| WO2006086760A3 (en) | Diagnostic measurement of disease | |
| Dias et al. | The challenge of treating orphan disease | |
| Serrão et al. | Annular lichen planus in association with Crohn disease | |
| Jagtap et al. | sMAdCAM: IL-6 (sMIL Index): A novel signature associated with COVID-19 disease progression and development of anti-SARS-CoV-2 antibodies | |
| AV | Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |